Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir vs. Protease Inhibitor in Treatment-Experienced HIV-1 Patients
NCT00298350Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2006
- Primary completion
- Jun 2007
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of elvitegravir in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Time-weighted average change from baseline in HIV RNA level through week 24. Started Feb 2006; status: completed.
02
Drugs
elvitegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00298350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298350.